Topotecan HCl

For research use only. Not for use in humans.

Catalog No.S1231 Synonyms: NSC609699, Nogitecan HCl, SKFS 104864A

15 publications

Topotecan HCl Chemical Structure

Molecular Weight(MW): 457.91

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 180 In stock
USD 320 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Topotecan HCl has been cited by 15 publications

2 Customer Reviews

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

  • Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells NF3vd45EgXSxdH;4bYPDqGG|c3H5 NVPqdmZLPzJiaB?= NGDWeZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJIlkPTB;MTDuUS=> M4rXflIxOzdzMUiz
human Bel7402 cells M336emN6fG:2b4jpZ:Kh[XO|YYm= NIG3VHo6PiCq NXzsWnpIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSmWuN{SwNkBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFwMjDuUS=> NXTSZ49KOTVzNkWxOFQ>
human HCT8 cells MWnDfZRwfG:6aXRCpIF{e2G7 NEfIelA6PiCq MoK5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVQCClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOUBvVQ>? NYXNUpljOTVzNkWxOFQ>
human MCF7 cells M{HndGN6fG:2b4jpZ:Kh[XO|YYm= M4DORlk3KGh? NFnsRYJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU45KG6P NXS1UpJpOTVzNkWxOFQ>
human A549 cells MVXDfZRwfG:6aXRCpIF{e2G7 M4rhR|k3KGh? M4\DOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlIhdk1? M{DRdFE2OTZ3MUS0
human colon carcinoma SW620 cell NWO2cYJqS3m2b4TvfIlkyqCjc4PhfS=> M13FU2N6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIHj1cYFvKGOxbH;uJINiemOrbn;tZUBUXzZ{MDDj[YxtKGyrbnWsJGlEPTB;Mz6yJI5O M4ra[FEzPDB6N{C3
human MESSA cells NVW1R3ZIS3m2b4TvfIlkyqCjc4PhfS=> NX7lcZlnPzJiaB?= Mn;xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUW0FiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUSgcm0> NHLubWszOTN2MU[3OC=>
human BGC823 cells NIDkbpFEgXSxdH;4bYPDqGG|c3H5 MmrwPVYhcA>? NXj2dYZ5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PC5|IH7N MWmxOVE3PTF2NB?=
human Ketr3 cells NIq2cpZEgXSxdH;4bYPDqGG|c3H5 M3LvcFk3KGh? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[ZRzOyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuPUBvVQ>? NWHDdnJ7OTVzNkWxOFQ>
LOX cells NGHX[nNEgXSxdH;4bYPDqGG|c3H5 NGHQXnBEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iTF;YJINmdGy|IDjt[Yxidm:vYTmgc4YhcHWvYX6geJVud3JiY3XscEBtcW6nczDifUB2e2mwZzDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> NFjHbms4QDV|M{Ox
human A549 cells MoLtSpVv[3Srb36gZZN{[Xl? MWm0JIg> MlLqRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PSCwTR?= M1\4TlE5OjB5N{S4
human H69 cells NWXpPYpxS3m2b4TvfIlkyqCjc4PhfS=> NXTuWFA5PzJiaB?= MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTZibl2= NILzT3QzOTN2MU[3OC=>
human A2780 cells MWDDfZRwfG:6aXRCpIF{e2G7 M2D5e|czKGh? MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> NXvL[FBuOjJ7NUmyOFY>
human LNCAP cells NYj6S5lpS3m2b4TvfIlkyqCjc4PhfS=> MoXnO|IhcA>? M{DUeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME25JI5O NGH4dngzOTN2MU[3OC=>
human HOP62 cells M1\FeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHztcZBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJV1B4MjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= NWroWJh7OjV7MEmyO|k>
human MCF7 cells NFKwUHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH7DUXRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= NEGyWHEzPTlyOUK3PS=>
human UACC62 cells M{Lpc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDVRWNEPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MXOyOVkxQTJ5OR?=
human DU145 cells MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? NULPR3ZWOjV7MEmyO|k>
LoVo cell line M3zWXmN6fG:2b4jpZ:Kh[XO|YYm= Ml\jR5l1d3SxeHnjJJBwfGWwdHnheIlwdiCxZjDUc5BwfGWlYX6gLHRRMSCkeTD0bIUh[2:vcH;1coQhcW5iKHj1cYFvKGOxbH;y[YN1[WxiY3HuZ4VzKEyxVn:gZ4VtdCCuaX7lMEBKSzVyPUGxMlYhdk1? MlLQNVI1ODh5MEe=
human lymphoblast tumor cell line RPM18402 NXLCPXgyS3m2b4TvfIlkyqCjc4PhfS=> Mo\vR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJlueGixYnzhd5QhfHWvb4KgZ4VtdCCuaX7lJHJRVTF6NECyMEBKSzVyPUGyJI5O Ml33NVI{QTJ5NEW=
human HL60 cells MmLrSpVv[3Srb36gZZN{[Xl? Ml3zRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwQVEzKG6P MU[xPVU1OTR6Mx?=
human A375 cells MkDxR5l1d3SxeHnjxsBie3OjeR?= NYjLTpFwPzJiaB?= NF;DN3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOzd3IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2xN{BvVQ>? MnfNNlE{PDF4N{S=
COR-L23/P cell M2T6W2N6fG:2b4jpZ:Kh[XO|YYm= MXvDfZRwfG:6aXPpeJkhdWWjc4Xy[YQhfXOrbnegeIhmKEORUj3MNlMheGG{ZX70ZYwhMEORUj3MNlMwWCliaIXtZY4hdm:wIIPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nLDDJR|UxRTF|LkKgcm0> MmPWNVE5ODZ5MkS=
human NCI-H460 cells M4HkcHBzd2yrZnXyZZRqd25iYYPzZZk> MoHjO|IhcA>? MmTxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N MX6yNVc5OzN4OR?=
human MOLT4 cells MV\DfZRwfG:6aXRCpIF{e2G7 Mn3QO|IhcA>? M{O2NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1QVFR2IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVkhdk1? MY[yOFkxODd{NR?=
human LoVo cells NXfRU4dIS3m2b4TvfIlkyqCjc4PhfS=> MnO0O|IhcA>? MmP5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUI9XdyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKwJI5O NWHLT2QyOjB|N{GxPFM>
RPM18402 tumor cell line MlP3VJJwdGmoZYLheIlwdiCjc4PhfS=> NV2xOIFIS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBqdiCUUF2xPFQxOiC2dX3vdkBk\WyuIHzpcoUtKEmFNUC9NlAhdk1? M2i1PVE2PDh{OUK5
human SN12C cells NUTiPGxGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLuS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P NEnmSHIzPTlyOUK3PS=>
human RPMI8226 cells NUDse2ltS3m2b4TvfIlkyqCjc4PhfS=> M2PIZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJRVUl6MkK2JINmdGy|IHL5JG1VXCCvZYToc4QtKEmFNUC9NlEhdk1? MVuxPVAyOjl7Nh?=
HT-29 cells NG[2[21EgXSxdH;4bYPDqGG|c3H5 Mk\0R5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEiWLUK5JINmdGy|KHPvcI9vMSCxZjDoeY1idiC2dX3vdkBk\WyuIHzpcoV{KGK7IIXzbY5oKE2WVDDhd5NigSxiSVO1NF0zPSCwTR?= NH;z[Yk4QDV|M{Ox
SK-BR-3 cells MV7DfZRwfG:6aXRCpIF{e2G7 NHW0flhKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZTCoV2suSlJvMzmsJGlEPTB;Mk[gcm0> NXPBfHlHOTF|M{S1Olk>
HeLa cells M3nNZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVTxSZl6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiSHXMZUBk\WyuczDh[pRmeiB2IHThfZMtKEeLNUC9N|Ahdk1? NWPDNJZoOTd2MUi1PFI>
UACC 62 cells M3POV2N6fG:2b4jpZ:Kh[XO|YYm= NYHVNGI1XGW|dHXkJIlvKH[rdILvJIZweiCleYTveI95cWOrdImgZYdicW6|dDDoeY1idiC2dX3vdkBk\WyuIHzpcoUhXUGFQzC2NkApdWWuYX7vcYEqNCCJSUWwQVMxKG6P NYHYR5NZOTB5MUS1NFI>
human HCT116 cells M{C5[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXj5OYlFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygS2k2OD1|MDDuUS=> NE\lWmYzPTlyOUK3PS=>
human lung cancer cell line (H128) NE\3WGJEgXSxdH;4bYPDqGG|c3H5 NEXOZodKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFixNlgqNCCLQ{WwQVMyKG6P MV2xNVM{PDV4OR?=
human MES-SA/Dx5 cells M{TnRWN6fG:2b4jpZ:Kh[XO|YYm= NVzyNXdZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2zN{BvVQ>? MWWyNVM1OTZ5NB?=
human A2780 cells M2rxe2N6fG:2b4jpZ:Kh[XO|YYm= M4jZ[lczKGh? NULXcpV4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{OyCwTR?= M3vXWVI1QTByN{K1
human MDA-MB-435 cells NFrvSFJEgXSxdH;4bYPDqGG|c3H5 NInHdng4OiCq NY\wbVVuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;M{Sgcm0> MUCyNlg3PzBzOR?=
human stomach cancer cell line (MKN45) NXnLTZVUS3m2b4TvfIlkyqCjc4PhfS=> NVWxXnFIUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;M{igcm0> MWmxNVM{PDV4OR?=
human KB3-1 cells NGLaSHZEgXSxdH;4bYPDqGG|c3H5 MlHmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgUXRVKGG|c3H5MEBKSzVyPUSwJI5O NETxSmoyQDh{OUOzOC=>
mouse P388 cells MkDxR5l1d3SxeHnjxsBie3OjeR?= NEPEcmlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBROzh6IHPlcIx{KGGodHXyJG1VXCCjc4PhfUwhUUN3ME20OUBvVQ>? MXexPFgzQTN|NB?=
A427 human lung carcinoma MULQdo9tcW[ncnH0bY9vKGG|c3H5 M3HM[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JI1m[XO3cnXkJIFo[Wmwc4SgRVQzPyCqdX3hckBtfW6pIHPhdoNqdm:vYTygTWM2OD12OTDuUS=> MWK5PFc3OTFz
human U251 cells M1joOWZ2dmO2aX;uJIF{e2G7 MYW2MVI1KGh? MYTJcohq[mm2aX;uJI9nKHSxcH;pd49u\XKjc3WtNUBqdiCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHnuJI52[2ynYYKg[Zh1emGldDDh[pRmeiB4IITvJFI1KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{NCCHQ{WwQVU1KG6P MoTrNlI{ODV4MUK=
human colon cancer cell line (WiDr) NIK3c|dEgXSxdH;4bYPDqGG|c3H5 M{XJUGlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsJIxqdmViKGfpSJIqNCCLQ{WwQVU3KG6P M3PLd|EyOzN2NU[5
human HepG2 cells M{S4R2N6fG:2b4jpZ:Kh[XO|YYm= NI\mTY41KGSjeYO= MmXaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME22NEBvVQ>? MV2xPFU2PDlyNh?=
human KB cells MXXDfZRwfG:6aXRCpIF{e2G7 Ml3MO|IhcA>? MnHxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIHHzd4F6NCCLQ{WwQVYzNjVibl2= MXWyOVAxQDR3Nh?=
human HCT8 cells Moq1R5l1d3SxeHnjxsBie3OjeR?= NYrSd5dDOyCmYYnz MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;N{Cgcm0> NYrOTY1qOjB|OUK1OFU>
human GBM2 cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 MUO3NkBp NELDdYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjF|IN88US=> NVLjNpdyOjZ|NUW1N|I>
SK-MEL-2 cells M3P1WGN6fG:2b4jpZ:Kh[XO|YYm= MmjSO|IhcA>? MnntR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVUWOLUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVAvOTRizszN M4n1cFIyOzRzNke0
human IGROV1 cells NFjjV2NEgXSxdH;4bYPDqGG|c3H5 MXi3NkBp NWOyVmhbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUUeUT2[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF4IN88US=> NEPZSWYzOTN2MU[3OC=>
human U87 cells NVP2U4diWHKxbHnm[ZJifGmxbjDhd5NigQ>? M17EUVQ5KGh? NX;WZokzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFch[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlE3KM7:TR?= MnzxNlQ5OjZ6MUi=
human HT1080 cells NUD2eYVOWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3nWdFQ5KGh? NITFVlZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNVA5OCClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxRTBwMUig{txO MV:yOlQxQDhzNR?=
human Hep3B cells MVnQdo9tcW[ncnH0bY9vKGG|c3H5 NH[xcVE4OiCq NFjo[2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmsJGdKPTB;MD6yNkDPxE1? M{XORVE6Pzl4OUW2
human GBM3 cells M2TlT3Bzd2yrZnXyZZRqd25iYYPzZZk> NFjL[HQ4OiCq MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlM5KM7:TR?= MVqyOlM2PTV|Mh?=
human KBVIN cells M3OwXGN6fG:2b4jpZ:Kh[XO|YYm= MlXZO|IhcA>? NULUNYI4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KYSV6gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjRizszN M3zlUFI2PDN6N{[5
human GBM1 cells NWX4OHRIWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkX6O|IhcA>? NI\mbpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjR4IN88US=> MYGyOlM2PTV|Mh?=
human U937 cells M3i4XGN6fG:2b4jpZ:Kh[XO|YYm= NF7NV3g1QCCq M2jZNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMh\XiycnXzd4lv\yCyNUOgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[Xli78{MJGlEPTB;MT6xJO69VQ>? MkC3NVk4OTV|MUm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3 / p62 ; 

PubMed: 23024792     


The indicated cells were treated with the indicated concentrations of topotecan for 24 h. The lysates were analysed by immunoblotting with The LC3 and P62 antibodies.

p53 / sesn2 / p-AMPK ; 

PubMed: 23024792     


HCT116 and LS-174T cells were treated with various concentrations of TPT for 24 h. The levels of P53, sestrin2 and p-AMPK were analysed by immunoblotting. 

23024792
Growth inhibition assay
Cell viability ; 

PubMed: 28544814     


Dose-response curves for topotecan (panel A) were determined in neuroblastoma cell lines The IC50 for the drugs are indicated. Changes in LAN-1 cell viablity as a function of different topotecan exposure times (panel B) were determined.

28544814
In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Formulation: PBS
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms NSC609699, Nogitecan HCl, SKFS 104864A
Smiles Cl.CCC1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC(=C(CN(C)C)C5=C4)O)C2=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04022876 Not yet recruiting Drug: ALRN-6924|Drug: Topotecan Small-cell Lung Cancer Aileron Therapeutics August 2019 Phase 1|Phase 2
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute April 23 2019 Early Phase 1
NCT03107988 Recruiting Drug: Lorlatinib|Drug: Cyclophosphamide|Drug: Topotecan Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids'' Cancer US/EU|Children''s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade''s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids'' Cancer September 1 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • Answer:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Topotecan HCl | Topotecan HCl supplier | purchase Topotecan HCl | Topotecan HCl cost | Topotecan HCl manufacturer | order Topotecan HCl | Topotecan HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID